Literature DB >> 6493161

Renal osteodystrophy in CAPD patients.

P Zucchelli, L Catizone, S Casanova, M Fusaroli, L Fabbri, G Ferrari.   

Abstract

To assess the influence of continuous ambulatory peritoneal dialysis (CAPD) on the evolution of renal osteodystrophy, we studied 36 adult patients with end-stage renal failure before starting dialysis and after 7-30 months. 17 patients (12 males and 5 females) were treated by CAPD as first treatment and 19 (14 males and 5 females) received maintenance hemodialysis. The two groups were age- and sex-matched and no patient received vitamin D. All patients had adequate clinical and metabolic follow-up with a radiological survey and quantitative bone histology at the start of dialysis and at the end of the study. Serum phosphate concentrations were much easier to control in CAPD than in hemodialysis patients. There was no difference in the evolutive pattern of vascular and periarticular calcifications in the two groups. The 25-hydroxyvitamin D3 levels were frequently lower in CAPD than in hemodialysis patients. In some CAPD patients, there was a significant loss of trabecular bone volume at the end of the study. The radiological and histological appearances of secondary hyperparathyroidism improved or seemed to worsen to a lesser degree in CAPD compared to hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6493161

Source DB:  PubMed          Journal:  Miner Electrolyte Metab        ISSN: 0378-0392


  2 in total

1.  Loss via peritoneal fluid as a factor for low 25(OH)D3 level in peritoneal dialysis patients.

Authors:  Garip Sahin; Ismail Kirli; Basar Sirmagul; Ertugrul Colak; Ahmet Ugur Yalcin
Journal:  Int Urol Nephrol       Date:  2009-04-29       Impact factor: 2.370

2.  Low bone volume--a risk factor for coronary calcifications in hemodialysis patients.

Authors:  Teresa Adragao; Johann Herberth; Marie-Claude Monier-Faugere; Adam J Branscum; Anibal Ferreira; Joao M Frazao; Jose Dias Curto; Hartmut H Malluche
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-21       Impact factor: 8.237

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.